Marker Therapeutics Inc. (MRKR)
1.04
-0.03 (-2.80%)
At close: Apr 10, 2025, 3:21 PM
-2.80% (1D)
| Bid | 1.04 |
| Market Cap | 11.19M |
| Revenue (ttm) | 6,591.1B |
| Net Income (ttm) | -10,731.3B |
| EPS (ttm) | -1.19 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | -0.95 |
| Analyst | Strong Buy |
| Ask | 1.07 |
| Volume | 20,136 |
| Avg. Volume (20D) | 134,331 |
| Open | 1.05 |
| Previous Close | 1.07 |
| Day's Range | 1.01 - 1.10 |
| 52-Week Range | 0.95 - 5.99 |
| Beta | 1.52 |
About MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2002
Employees 8
Stock Exchange NASDAQ
Ticker Symbol MRKR
Analyst Forecast
According to 3 analyst ratings, the average rating for MRKR stock is "Strong Buy." The 12-month stock price forecast is $12.5, which is an increase of 1096.17% from the latest price.
Stock ForecastsEarnings Surprise
Marker Therapeutics has released their quartely earnings
on Mar 31, 2025:
Next Earnings Release
Marker Therapeutics Inc. is scheduled to release its earnings on May 14, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+33.33%
Marker Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
3 months ago
-7.44%
Marker Therapeutics shares are trading lower. The company reported results from its Phase 1 APOLLO study of MT-601 in relapsed Lymphoma.